<DOC>
	<DOCNO>NCT01641965</DOCNO>
	<brief_summary>Timing initiate domiciliary invasive ventilation ( NIV ) amyotrophic lateral sclerosis patient remain unclear . The hypothesis study early use NIV , initial phase respiratory muscle weakness , improve prognosis ALS patient . Principal objective : To evaluate impact early NIV survival ALS patient . Secondary objective : To determine effect early NIV progression respiratory muscle weakness . To analyze impact early NIV quality life ALS patient . To evaluate correlation FVC parameter respiratory evaluation ( maximal inspiratory pressure ( MIP ) , sniff nasal inspiratory pressure ( SNP ) , nocturnal desaturation ) utility early indication NIV . To evaluate tolerance early NIV . Methods : multicentric , randomize , open-label , control clinical trial parallel treatment design . Patients include FVC reach threshold 75 % predict value randomize : Group A : NIV treatment begin immediately Group B : NIV treatment start patient fulfil least one follow criterion : ( ) FVC &lt; 50 % predict , ( ii ) orthopnea , and/or ( iii ) PaCO2 &gt; 45 mmHg . Follow-up visit do every three month pulmonary function test , nocturnal pulse oximetry , quality life quality sleep test , assessment disease progression ( ALSFSR-R scale ) , tolerance compliance NIV .</brief_summary>
	<brief_title>Impact Early Non Invasive Ventilation Amyotrophic Lateral Sclerosis ( ALS ) Patients</brief_title>
	<detailed_description>ALS patient early impairment respiratory muscle ( FVC around 75 % ) radomised initiate NIV conventional follow-up . The NIV treatment initiate hospital model ventilator VIVO 40 ( BREAS Medical AD , Sweden ) use pressure support assisted/control mode , minimum pressure support 10 cm . Initial NIV indication group patient nocturnal . Patients define tolerant NIV refer inconvenience able asleep NIV . The efficacy intervention compare group survival death change invasive tracheal ventilation prymary efficacy parameter .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Participant willing able give inform consent participation study Definite ALS diagnosis accord El Escorial Criteria Ability understand perform pulmonary function test FVC â‰¤ 75 % ( FVC registry &gt; 75 % document within six previous month ) Major comorbidity ( nonrelated ALS ) shorten life expectancy Cognitive impairment prevents patient understand perform study procedure include technically acceptable pulmonary function test ( FVC , MIP , SNP , PCF ) Patient refusal NIV treatment Previous respiratory cardiac disease know impaired spirometry Indication NIV accord standard criterion ( PaCO2 &gt; 45 mmHg , FVC &lt; 50 % , orthopnea ) ALS slow disease progression ( 3 year ) Participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>